Carlos Singer
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,300 of the $4,403 with a category attached, or 74.9%. Amneal Pharmaceuticals LLC accounts for 80.1% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $3,591 and has fallen 97.2% since, to $102 in 2025.
Across 31 payments — averaging $142.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amneal Pharmaceuticals LLC$4K
- AbbVie$331
- Neurocrine Biosciences, Inc.$300
- Boston Scientific$185
- Merz Pharmaceuticals, LLC$29
- Ipsen Biopharmaceuticals, Inc$19
- plus $12 from 1 others
Across 195 payments — averaging $3137.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sunovion Pharmaceuticals Inc.$372K
- Amneal Pharmaceuticals LLC$150K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$88K
- Biogen$1K
What the payments were for
- Speaking & faculty fees$3,30075%
- Travel & lodging$1564%
- Food & beverage$94722%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amneal Pharmaceuticals LLC | 3 | $3,528 |
| AbbVie | 20 | $331 |
| Neurocrine Biosciences, Inc. | 4 | $300 |
| Boston Scientific | 1 | $185 |
| Merz Pharmaceuticals, LLC | 1 | $29 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYTARY$3,528
- GENERAL DBS$185
How this compares
$4,403 in reported general payments places this provider in the 60th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 43 | $208,826 |
| NourianzIstradefylline | 53 | $109,699 |
| RytaryCarbidopa/Levodopa | 121 | $104,701 |
| NeuproRotigotine | 60 | $85,407 |
| GocovriAmantadine Hcl | 20 | $60,762 |
| InbrijaLevodopa | 42 | $60,123 |
| MyrbetriqMirabegron | 35 | $18,836 |
| OngentysOpicapone | 20 | $16,317 |
| XadagoSafinamide Mesylate | 14 | $15,971 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 616 | $14,747 |
| NamzaricMemantine Hcl/Donepezil Hcl | 14 | $10,467 |
| Entacapone | 43 | $8,371 |
| Rasagiline Mesylate | 36 | $6,219 |
| Carbidopa | 29 | $4,131 |
| Midodrine Hcl | 22 | $4,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $12 | $208,82643 claims |
| Amneal Pharmaceuticals LLCRytary | $3,528 | $104,701121 claims |
| Neurocrine Biosciences, Inc.Ongentys | $300 | $16,31720 claims |
| AbbVieNamzaric | $331 | $10,46714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,434 neurology providers in Florida.
Other neurology in Miami
- Diego Torres-RussottoMiami$652K
- Bruno GalloMiami$313K
- Brad HerskowitzMiami$273K
- Flavia NelsonMiami$264K
- Corneliu LucaMiami$257K
- Kottil RammohanMiami$176K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.